Recently, antibodies targeting programmed cell death 1 (PD‐1) or its ligand (PD‐L1) have shifted the treatment paradigm of advanced NSCLC without driver gene alterations.1, 2, 3. This evidence concerns the gene CD274 and non-small cell lung carcinoma.